The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo Nordisk's patent on its branded version, known as ...

Recent health news includes trade restrictions on Brazilian chicken due to bird flu, potential U.S. tariffs on ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded ...

Novo Nordisk said it's ending its collaboration due to concerns with Hims & Hers the company's sales and promotion of cheap knock-offs of the weight loss drug Wegovy, it said on Monday.

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

A Novo Nordisk challenge to the Medicare price negotiation program is being closely watched Adobe By John Wilkerson April 21, 2025 Washington Correspondent ...

When should six drugs count as one? That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against the federal government. And the answer could have ...

Novo’s portfolio has high exposure to Medicare, and the firm faced pressure due to US legislation that increased the portion of the Medicare Part D donut hole covered by manufacturers in 2019 ...

In Novo’s case, the New Jersey federal court sided with the Centers for Medicare & Medicaid Services last year and upheld the program’s legality and finding that the court could not review the price ...

Shares in Novo Nordisk, which sells GLP-1s Wegovy for weight loss and Ozempic for diabetes, and Eli Lilly, which sells Zepbound, fell after the news was announced after market close Friday.